Polyrizon reported that its PL‑16 Viral Blocker achieved 100 % inhibition of several respiratory viruses in cell‑culture assays, including influenza A (H1N1) and a panel of coronaviruses. The hydrogel formulation prevented virus‑induced cytopathic effects while maintaining high host‑cell viability, and the effect was fully reversible when the gel was removed, confirming a physical barrier mechanism rather than viral inactivation.
The reversible nature of the blockade is a core feature of Polyrizon’s Capture & Contain platform. By forming a temporary, non‑pharmacological film inside the nasal cavity, the gel blocks viral particles from contacting epithelial cells. Because the barrier can be removed without leaving residual antiviral activity, the product can be used repeatedly without the risk of drug resistance or systemic exposure.
CEO Tomer Izraeli said the results “reinforce the unique nature of our platform. Demonstrating both strong viral blocking and reversibility is key to establishing the non‑pharmacological, safe, and effective nature of our nasal protection.” The quote underscores the company’s strategy to differentiate itself from conventional antiviral drugs and to address unmet needs in respiratory protection.
Polyrizon remains a development‑stage company with no current revenue and a history of negative earnings. The firm has faced Nasdaq listing challenges but has been granted continued compliance. The company plans to pursue a De Novo Class II medical‑device classification for PL‑16, with pivotal clinical trials slated for 2026. The in‑vitro success provides a critical preclinical milestone that will support regulatory submissions and future funding rounds.
The positive data position Polyrizon to advance its pipeline of nasal‑spray products, including PL‑14 for allergies and PL‑15 for COVID‑19. By offering a non‑pharmacological, reversible barrier, the company could capture a niche in the respiratory protection market that is currently dominated by pharmacological antivirals and vaccines. The results also strengthen investor confidence in the company’s technology platform, despite its ongoing financial challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.